CER To Play A Larger Role In Investment Decisions – Merck's McElwee
Executive Summary
Pharmaceutical companies are going to need to consider the impact of the growing emphasis on comparative effectiveness earlier in the drug development and investment decision process, Merck & Co.'s Newell McElwee said.
You may also be interested in...
Stimulus-Funded CER: Few Awards Are For Drug Vs. Drug Studies
Pitting one drug against another proved not to be a key focus of the comparative effectiveness research funding given from the $1.1 billion set aside for CER in the American Recovery and Reinvestment Act.
Stimulus-Funded CER: Few Awards Are For Drug Vs. Drug Studies
Pitting one drug against another proved not to be a key focus of the comparative effectiveness research funding given from the $1.1 billion set aside for CER in the American Recovery and Reinvestment Act.
Pfizer's Lewis-Hall To Represent Pharma Interests On PCORI Board
Freda Lewis-Hall was among nominations from both BIO and PhRMA to sit on governing board of new comparative effectiveness entity created under the health care reform law.